Abstract 1944P
Background
This study aims to describe the Super enhancers (SEs) landscape in 5-FU resistant GC, and to illustrate the biological mechanism of SE-driven NR3C1 mediating 5-FU resistance.
Methods
The ChIP-Seq and ROSE algorithms were applied to calculate SE in induced 5-FU resistanceGC cells. The correlation between NR3C1 expression and the sensitivity to 5-FU was verified by drug sensitivity curves. Confocal microscopy was used to observe the purified NR3C1 fluorescent protein droplets in vitro, and to observe dynamic droplets in the nucleus. FRAP verified the droplet fluidity. CUT&Tag of NR3C1 was applied to analyze the co-binding pattern between NR3C1 and SE on the genome. PDX models and GC cells were used to evaluate the inhibitory effect of epigenetic inhibitors JQ1 on NR3C1 and its target genes, and to improve 5-FU responsivity in GC cells.
Results
The SE profiles of 5-FU-sensitive, spontaneously resistant and induced resistant cells were described. SiRNA libraries were used to identify the master TF NR3C1. The 5-FU drug sensitivity curve verified that GC cells with high NR3C1 expression were resistant to 5-FU. Moreover, NR3C1 expression was increased in 5-FU-resistant cells, and knocking down NR3C1 in resistant cells could restore the 5-FU sensitivity. NR3C1 inhibition also improved the sensitivity of GC organoids to 5-FU. NR3C1 protein formed phase separation in vitro, and also formed droplets in the nucleus, together with transcription cofactors. With NR3C1 knockdown, SE profile changed through enhancer reprogramming, and the SE-associated genes transcription was inhibited. Then, NR3C1 downstream target genes, which were associated with 5-FU resistance, were significantly reduced. The use of JQ1 effectively inhibited the expression of downstream target genes, and efficiently improve the tumor inhibition effect of 5-FU in PDX models.
Conclusions
The high expression of NR3C1 driven by SE is positively correlated with 5-FU resistance in GC patients. SE-driven NR3C1 formed phase separation at the SE region in the nucleus, activating the positive feedback loop of TF. SE-driven NR3C1 strongly promotes the transcription of downstream target genes and mediates the resistance of GC to 5-FU. JQ1 can effectively improve the 5-FU sensitivity of GC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1842P - The experience of women with breast or gynecological cancer after participation in the online mindfulness-based cancer recovery program (eMBCR)
Presenter: Marie-Estelle Gaignard
Session: Poster session 12
1843P - Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial
Presenter: Davide Smussi
Session: Poster session 12
1844P - 3-year experience of the Belgian multidisciplinary immunotoxicity board (BITOX): A nationwide initiative of the Belgian Society of Medical Oncology (BSMO)
Presenter: Marthe Verhaert
Session: Poster session 12
1845P - The impact of body mass index (BMI) on immune-related adverse events (irAEs) and acute care use among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Zac Coyne
Session: Poster session 12
1846P - Social determinants of health in studies assessing toxicities associated with immune checkpoint inhibitor treatment: A systematic review
Presenter: Sofia Georgopoulou
Session: Poster session 12
1847P - Safety and efficacy of immune checkpoint inhibitors in patients over 85 years: ICIPO85 study
Presenter: MYRTILLE THOMAS
Session: Poster session 12
1848P - Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: Multicentre experience
Presenter: Onur Bas
Session: Poster session 12
1849P - Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort
Presenter: Víctor Albarrán Fernández
Session: Poster session 12
1850P - Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors
Presenter: Jesús Peña-Lopez
Session: Poster session 12
1851P - Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis
Presenter: Taha Koray Sahin
Session: Poster session 12